GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sienna Biopharmaceuticals Inc (OTCPK:SNNAQ) » Definitions » Current Ratio
中文

Sienna Biopharmaceuticals (Sienna Biopharmaceuticals) Current Ratio : 15.27 (As of Sep. 2019)


View and export this data going back to 2017. Start your Free Trial

What is Sienna Biopharmaceuticals Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Sienna Biopharmaceuticals's current ratio for the quarter that ended in Sep. 2019 was 15.27.

Sienna Biopharmaceuticals has a current ratio of 15.27. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.

The historical rank and industry rank for Sienna Biopharmaceuticals's Current Ratio or its related term are showing as below:

SNNAQ's Current Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 3.795
* Ranked among companies with meaningful Current Ratio only.

Sienna Biopharmaceuticals Current Ratio Historical Data

The historical data trend for Sienna Biopharmaceuticals's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sienna Biopharmaceuticals Current Ratio Chart

Sienna Biopharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18
Current Ratio
5.59 1.06 9.39 2.07

Sienna Biopharmaceuticals Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.86 2.07 2.61 2.43 15.27

Competitive Comparison of Sienna Biopharmaceuticals's Current Ratio

For the Biotechnology subindustry, Sienna Biopharmaceuticals's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sienna Biopharmaceuticals's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sienna Biopharmaceuticals's Current Ratio distribution charts can be found below:

* The bar in red indicates where Sienna Biopharmaceuticals's Current Ratio falls into.



Sienna Biopharmaceuticals Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Sienna Biopharmaceuticals's Current Ratio for the fiscal year that ended in Dec. 2018 is calculated as

Current Ratio (A: Dec. 2018 )=Total Current Assets (A: Dec. 2018 )/Total Current Liabilities (A: Dec. 2018 )
=50.412/24.349
=2.07

Sienna Biopharmaceuticals's Current Ratio for the quarter that ended in Sep. 2019 is calculated as

Current Ratio (Q: Sep. 2019 )=Total Current Assets (Q: Sep. 2019 )/Total Current Liabilities (Q: Sep. 2019 )
=19.731/1.292
=15.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sienna Biopharmaceuticals  (OTCPK:SNNAQ) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Sienna Biopharmaceuticals Current Ratio Related Terms

Thank you for viewing the detailed overview of Sienna Biopharmaceuticals's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sienna Biopharmaceuticals (Sienna Biopharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
30699 Russell Ranch Road, Suite 140, Westlake Village, CA, USA, 91362
Sienna Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on bringing innovations in biotechnology to the discovery, development, and commercialization of first-in-class, targeted, topical products in medical dermatology and aesthetics. The objective is to develop multi-asset pipeline of topical therapies that enhance the health, appearance, and quality of life of dermatology patients. The product portfolio includes SNA-120, SNA-125, and SNA-001.
Executives
Alexander Azoy officer: Chief Financial Officer 30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Timothy K. Andrews officer: General Counsel & Secretary 30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Iii Frederick Beddingfield director, officer: President & CEO C/O KYTHERA BIOPHARMACEUTICALS, INC. 27200 WEST AGOURA ROAD, SUITE 200 CALABASAS CA 91301
Paul F. Lizzul officer: Chief Medical Officer 30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Diane Stroehmann officer: See Remarks 30699 RUSSELL RANCH ROAD SUITE 140 WESTLAKE VILLAGE CA 91362
Dennis M Fenton director
Todd Harris director 30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Kristina Burow director, 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Robert J More director 680 S CACHE STREET, SUITE 100, BOX 10820, JACKSON WY 83001
James M. Hindman director 2525 DUPONT DRIVE, IRVINE CA 92612
Keith R Leonard director ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Arch Venture Partners Viii, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Fund Viii Overage, L.p. 10 percent owner C/O ARCH VENTURE PARTNERS VIII, LLC, 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Fund X Overage, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners X Overage, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631

Sienna Biopharmaceuticals (Sienna Biopharmaceuticals) Headlines